COMMUNIQUÉS West-GlobeNewswire

AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019
26/09/2019
Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month XLRP dose expansion data demonstrates [...]
Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
26/09/2019
DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat [...]
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26/09/2019
STAMFORD, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by [...]
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
26/09/2019
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
26/09/2019
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS ( F unctional O utcomes in a R andomized T rial of I [...]
Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
26/09/2019
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate [...]
European Commission Approves Trogarzo®
26/09/2019
MONTREAL, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo ® (ibalizumab) was approved today by the European Commission. “The approval of [...]
La Commission européenne approuve Trogarzo(MD)
26/09/2019
MONTRÉAL, 26 sept. 2019 (GLOBE NEWSWIRE) -- Theratechnologies inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que Trogarzo MD (ibalizumab) a été approuvée par la Commission européenne. « L’approbation de [...]
Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT
26/09/2019
TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE [...]
Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019
26/09/2019
This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its Annual General Meeting ( [...]
2019 Half-year consolidated results: Deinove’s progress coming to fruition
26/09/2019
2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections Communication by [...]
Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE
26/09/2019
Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE Lancement de l’essai de Phase II testant DNV3837 en traitement de première ligne des infections gastrointestinales sévères à Clostridioides [...]
Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference
26/09/2019
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel [...]
Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
26/09/2019
DEVON, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Nicox : Rapport semestriel 2019
26/09/2019
Communiqué de presse Nicox : Rapport semestriel 2019 26 septembre 2019 Sophia Antipolis, France Le rapport financier semestriel au 30 juin 2019 de la société Nicox SA (Euronext Paris: FR0013018124, COX, éligible PEA-PME [...]
Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH
26/09/2019
Designation is intended to facilitate the development and expedite the regulatory review of lanifibranor for the treatment of NASH Daix (France), September 26, 2019 – Inventiva (Euronext: IVA), a clinical-stage [...]
Inventiva obtient le statut « Fast Track » de la FDA pour son produit candidat phare, lanifibranor, dans la NASH
26/09/2019
Ce statut est destiné à faciliter le développement et à accélérer l’examen réglementaire de lanifibranor pour le traitement de la NASH Daix (France), le 26 septembre 2019 – Inventiva (Euronext : IVA), société [...]
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
26/09/2019
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed with multiple myeloma [...]
Disclosure of a transparency notification
26/09/2019
PRESS RELEASE : REGULATED INFORMATION 26 September 2019, 17:40 CEST Disclosure of a transparency notification Mechelen, Belgium, 26 September 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative [...]

Pages